Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 367 articles:
HTML format
Text format



Single Articles


    September 2018
  1. ACEVEDO F, Armengol VD, Deng Z, Tang R, et al
    Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4962.
    PubMed     Text format     Abstract available


  2. LEE SK, Kim SW, Yu JH, Lee JE, et al
    Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4947.
    PubMed     Text format     Abstract available


  3. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4944.
    PubMed     Text format     Abstract available


  4. NIRAULA S, Gyawali B
    Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4967.
    PubMed     Text format     Abstract available


  5. TONG WL, Callahan BM, Tu YN, Zaman S, et al
    Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
    Breast Cancer Res Treat. 2018 Sep 18. pii: 10.1007/s10549-018-4961.
    PubMed     Text format     Abstract available


  6. FALATO C, Taylor SK, Szulkin R, Nordblom A, et al
    Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4936.
    PubMed     Text format     Abstract available


  7. LIU Z, Sahli Z, Wang Y, Wolff AC, et al
    Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4950.
    PubMed     Text format     Abstract available


  8. SPRING L, Niemierko A, Haddad S, Yuen M, et al
    Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
    Breast Cancer Res Treat. 2018 Sep 15. pii: 10.1007/s10549-018-4959.
    PubMed     Text format     Abstract available


  9. RYU JM, Choi HJ, Kim I, Lee SK, et al
    Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4948.
    PubMed     Text format     Abstract available


  10. KHALED H, Gamal H, Lotayef M, Knauer M, et al
    The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4945.
    PubMed     Text format     Abstract available


  11. OLIVA-MORENO J, Pena-Longobardo LM
    Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4963.
    PubMed     Text format     Abstract available


  12. JEON SH, Shin KH, Kim JH, Kim K, et al
    Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4966.
    PubMed     Text format     Abstract available


  13. PEREZ-PENA J, Gyorffy B, Amir E, Pandiella A, et al
    Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
    Breast Cancer Res Treat. 2018 Sep 11. pii: 10.1007/s10549-018-4965.
    PubMed     Text format     Abstract available


  14. TAKADA M, Sugimoto M, Masuda N, Iwata H, et al
    Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
    Breast Cancer Res Treat. 2018 Sep 7. pii: 10.1007/s10549-018-4958.
    PubMed     Text format     Abstract available


  15. FENTIMAN IS
    Surgical options for male breast cancer.
    Breast Cancer Res Treat. 2018 Sep 5. pii: 10.1007/s10549-018-4952.
    PubMed     Text format     Abstract available


  16. ALTUNDAG K
    Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients.
    Breast Cancer Res Treat. 2018 Sep 3. pii: 10.1007/s10549-018-4949.
    PubMed     Text format    


  17. OZAWA PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, et al
    Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
    Breast Cancer Res Treat. 2018 Sep 1. pii: 10.1007/s10549-018-4925.
    PubMed     Text format     Abstract available


    August 2018
  18. NAROD SA, Giannakeas V, Sopik V
    Time to death in breast cancer patients as an indicator of treatment response.
    Breast Cancer Res Treat. 2018 Aug 30. pii: 10.1007/s10549-018-4935.
    PubMed     Text format     Abstract available


  19. SHEN S, Unger JM, Crew KD, Till C, et al
    Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4946.
    PubMed     Text format     Abstract available


  20. MOORE AH, Trentham-Dietz A, Burns M, Gangnon RE, et al
    Obesity and mortality after locoregional breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4932.
    PubMed     Text format     Abstract available


  21. ZHANG Z, Li C, Fan H, Xiang Q, et al
    Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4942.
    PubMed     Text format     Abstract available


  22. DE SOUZA TIMOTEO AR, Goncalves AEMM, Sales LAP, Albuquerque BM, et al
    A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4938.
    PubMed     Text format     Abstract available


  23. THOMAS R, Rowell R, Crichton S, Cain H, et al
    Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4943.
    PubMed     Text format     Abstract available


  24. FRONTERA ED, Khansa RM, Schalk DL, Leakan LE, et al
    IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2018 Aug 28. pii: 10.1007/s10549-018-4941.
    PubMed     Text format     Abstract available


  25. GOTO-YAMAGUCHI L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, et al
    Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4933.
    PubMed     Text format     Abstract available


  26. YANG J, Lv Q
    Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4926.
    PubMed     Text format    


  27. ALTUNDAG K
    Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Aug 24. pii: 10.1007/s10549-018-4934.
    PubMed     Text format    


  28. BALLINGER TJ, Reddy A, Althouse SK, Nelson EM, et al
    Impact of primary breast cancer therapy on energetic capacity and body composition.
    Breast Cancer Res Treat. 2018 Aug 22. pii: 10.1007/s10549-018-4924.
    PubMed     Text format     Abstract available


  29. WANG B, Yuan F
    The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4929.
    PubMed     Text format    


  30. BAE SY, Nam SJ, Jung Y, Lee SB, et al
    Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4928.
    PubMed     Text format     Abstract available


  31. BEMANIAN V, Noone JC, Sauer T, Touma J, et al
    Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4927.
    PubMed     Text format     Abstract available


  32. SONG EJ, Lee CW, Jung SY, Kim BN, et al
    Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4915.
    PubMed     Text format     Abstract available


  33. RAMOS J, Das J, Felty Q, Yoo C, et al
    NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Breast Cancer Res Treat. 2018 Aug 20. pii: 10.1007/s10549-018-4905.
    PubMed     Text format     Abstract available


  34. CLAESSENS AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, et al
    Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Breast Cancer Res Treat. 2018 Aug 18. pii: 10.1007/s10549-018-4906.
    PubMed     Text format     Abstract available


  35. KENN M, Cacsire Castillo-Tong D, Singer CF, Cibena M, et al
    Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
    Breast Cancer Res Treat. 2018 Aug 16. pii: 10.1007/s10549-018-4920.
    PubMed     Text format     Abstract available


  36. KRABY MR, Valla M, Opdahl S, Haugen OA, et al
    The prognostic value of androgen receptors in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Aug 14. pii: 10.1007/s10549-018-4904.
    PubMed     Text format     Abstract available


  37. BUHL ASK, Christensen TD, Christensen IJ, Nelausen KM, et al
    Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4918.
    PubMed     Text format     Abstract available


  38. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4919.
    PubMed     Text format     Abstract available


  39. BARBOSA C ROCHA F, Falcone AB, Buzaid AC, Pimenta JM, et al
    Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4912.
    PubMed     Text format     Abstract available


  40. GREEN AK, Aviki EM, Matsoukas K, Patil S, et al
    Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4909.
    PubMed     Text format     Abstract available


  41. BORRIE AE, Rose RV, Choi YH, Perera FE, et al
    Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4910.
    PubMed     Text format     Abstract available


  42. LEE SB, Ko SS, Park CH, Nam SJ, et al
    Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4892.
    PubMed     Text format     Abstract available


  43. CHEN BT, Jin T, Patel SK, Ye N, et al
    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4911.
    PubMed     Text format     Abstract available


  44. BAE SY, Kim SJ, Lee J, Lee ES, et al
    Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4908.
    PubMed     Text format     Abstract available


  45. MURPHY J, Pfeiffer RM, Lynn BCD, Caballero AI, et al
    Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.
    Breast Cancer Res Treat. 2018 Aug 6. pii: 10.1007/s10549-018-4907.
    PubMed     Text format     Abstract available


  46. ZDRAVKOVIC D, Nikolic D, Zdravkovic M
    Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?
    Breast Cancer Res Treat. 2018 Aug 4. pii: 10.1007/s10549-018-4913.
    PubMed     Text format    


  47. LIN CH, Tang CH
    Rebuttal comments on "Glucocorticoids in breast cancer treatment: Real benefit or selection bias?"
    Breast Cancer Res Treat. 2018 Aug 2. pii: 10.1007/s10549-018-4872.
    PubMed     Text format    


    July 2018
  48. SANFT T, Usiskin I, Harrigan M, Cartmel B, et al
    Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4895.
    PubMed     Text format     Abstract available


  49. SUN F, Hall A, Tighe MP, Brunelle CL, et al
    Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4902.
    PubMed     Text format     Abstract available


  50. FELIZ-MOSQUEA YR, Christensen AA, Wilson AS, Westwood B, et al
    Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4884.
    PubMed     Text format     Abstract available


  51. KUROZUMI S, Joseph C, Sonbul S, Aleskandarany MA, et al
    Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4891.
    PubMed     Text format     Abstract available


  52. MESSINA C, Cattrini C, Buzzatti G, Cerbone L, et al
    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4901.
    PubMed     Text format     Abstract available


  53. LIN JH, Tu SH, Chen LC, Huang CC, et al
    Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4897.
    PubMed     Text format     Abstract available


  54. GUNER G, Dizdar O
    Glucocorticoids in breast cancer treatment: real benefit or selection bias?
    Breast Cancer Res Treat. 2018 Jul 26. pii: 10.1007/s10549-018-4871.
    PubMed     Text format    


  55. FARSHID G, Walters D
    Molecular subtypes of screen-detected breast cancer.
    Breast Cancer Res Treat. 2018 Jul 25. pii: 10.1007/s10549-018-4899.
    PubMed     Text format     Abstract available


  56. MADDEN JM, Murphy L, Zgaga L, Bennett K, et al
    De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4896.
    PubMed     Text format     Abstract available


  57. SHARIF-ASKARI B, Amrein L, Aloyz R, Panasci L, et al
    PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4888.
    PubMed     Text format     Abstract available


  58. WULANINGSIH W, Garmo H, Ahlgren J, Holmberg L, et al
    Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
    Breast Cancer Res Treat. 2018 Jul 21. pii: 10.1007/s10549-018-4890.
    PubMed     Text format     Abstract available


  59. TERADA M, Adachi Y, Sawaki M, Hattori M, et al
    Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Jul 20. pii: 10.1007/s10549-018-4898.
    PubMed     Text format     Abstract available


  60. SOLDERA SV, Ennis M, Lohmann AE, Goodwin PJ, et al
    Sexual health in long-term breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jul 19. pii: 10.1007/s10549-018-4894.
    PubMed     Text format     Abstract available


  61. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4893.
    PubMed     Text format     Abstract available


  62. MCCALL NS, Simone BA, Mehta M, Zhan T, et al
    Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4880.
    PubMed     Text format     Abstract available


  63. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jul 16. pii: 10.1007/s10549-018-4883.
    PubMed     Text format     Abstract available


  64. VAN NULAND M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, et al
    Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4886.
    PubMed     Text format     Abstract available


  65. O'BRIEN KM, Mooney T, Fitzpatrick P, Sharp L, et al
    Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4877.
    PubMed     Text format     Abstract available


  66. REDITI M, Messina C
    Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4885.
    PubMed     Text format    


  67. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Pantel K, et al
    The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4882.
    PubMed     Text format     Abstract available


  68. SAHA A, Harowicz MR, Cain EH, Hall AH, et al
    Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
    Breast Cancer Res Treat. 2018 Jul 10. pii: 10.1007/s10549-018-4879.
    PubMed     Text format     Abstract available


  69. NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
    Breast cancer and its impact in male transsexuals.
    Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
    PubMed     Text format     Abstract available


  70. ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
    Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
    PubMed     Text format     Abstract available


  71. ROBINSON A, Souied O, Bota AB, Levasseur N, et al
    Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
    PubMed     Text format     Abstract available


  72. WANG J, Xu B, Wang W, Zhai X, et al
    Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
    PubMed     Text format     Abstract available


  73. KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
    Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
    PubMed     Text format     Abstract available


  74. BERTHE A, Zaffino M, Muller C, Foulquier F, et al
    Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
    PubMed     Text format     Abstract available


  75. SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
    Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
    PubMed     Text format     Abstract available


    June 2018
  76. BRENNAN M, Gass P, Haberle L, Wang D, et al
    The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Breast Cancer Res Treat. 2018 Jun 27. pii: 10.1007/s10549-018-4829.
    PubMed     Text format     Abstract available


  77. STOUT NK, Cronin AM, Uno H, Ozanne EM, et al
    Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Breast Cancer Res Treat. 2018 Jun 26. pii: 10.1007/s10549-018-4860.
    PubMed     Text format     Abstract available


  78. LEE DY, Park YH, Lee JE, Choi D, et al
    Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4863.
    PubMed     Text format     Abstract available


  79. VAN SWEARINGEN AED, Siegel MB, Deal AM, Sambade MJ, et al
    LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4852.
    PubMed     Text format     Abstract available


  80. YAP YS, Munusamy P, Lim C, Chan CHT, et al
    Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4851.
    PubMed     Text format     Abstract available


  81. KIM JY, Lim JE, Jung HH, Cho SY, et al
    Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4858.
    PubMed     Text format     Abstract available


  82. BAUER ECA, Schochter F, Widschwendter P, DeGregorio A, et al
    Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4856.
    PubMed     Text format     Abstract available


  83. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jun 19. pii: 10.1007/s10549-018-4855.
    PubMed     Text format     Abstract available


  84. PEREIRA PTVT, Reis AD, Diniz RR, Lima FA, et al
    Dietary supplements and fatigue in patients with breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4857.
    PubMed     Text format     Abstract available


  85. JERZAK KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, et al
    Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4844.
    PubMed     Text format     Abstract available


  86. KOGAWA T, Fujii T, Fouad TM, Liu DD, et al
    Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4853.
    PubMed     Text format     Abstract available


  87. LI X, Zhang Y, Meisel J, Jiang R, et al
    Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
    Breast Cancer Res Treat. 2018 Jun 15. pii: 10.1007/s10549-018-4832.
    PubMed     Text format     Abstract available


  88. LANGBALLE R, Frederiksen K, Jensen MB, Andersson M, et al
    Mortality after contralateral breast cancer in Denmark.
    Breast Cancer Res Treat. 2018 Jun 11. pii: 10.1007/s10549-018-4846.
    PubMed     Text format     Abstract available


  89. MANDUJANO-TINOCO EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V, et al
    New emerging roles of microRNAs in breast cancer.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4850.
    PubMed     Text format     Abstract available


  90. SMITH BL, Gadd MA, Lanahan CR, Rai U, et al
    Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4845.
    PubMed     Text format     Abstract available


  91. LOTSCH J, Sipila R, Tasmuth T, Kringel D, et al
    Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
    Breast Cancer Res Treat. 2018 Jun 6. pii: 10.1007/s10549-018-4841.
    PubMed     Text format     Abstract available


  92. KONG AL, Nattinger AB, McGinley E, Pezzin LE, et al
    The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4837.
    PubMed     Text format     Abstract available


  93. ROUMELIOTIS M, Long K, Phan T, Graham D, et al
    Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4848.
    PubMed     Text format     Abstract available


  94. CHA YJ, Ahn SG, Bae SJ, Yoon CI, et al
    Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4842.
    PubMed     Text format     Abstract available


  95. PICADO O, Khazeni K, Allen C, Yakoub D, et al
    Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4840.
    PubMed     Text format     Abstract available


  96. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
    PubMed     Text format     Abstract available


  97. REDDY JP, Atkinson RL, Larson R, Burks JK, et al
    Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4835.
    PubMed     Text format     Abstract available


  98. ARIAS-PULIDO H, Cimino-Mathews A, Chaher N, Qualls C, et al
    The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4834.
    PubMed     Text format     Abstract available


  99. EVANS A, Sim YT, Pourreyron C, Thompson A, et al
    Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4836.
    PubMed     Text format     Abstract available


    May 2018
  100. JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
    Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
    PubMed     Text format     Abstract available


  101. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
    PubMed     Text format     Abstract available


  102. JACOB L, Scholten PC, Kostev K, Kalder M, et al
    Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
    PubMed     Text format     Abstract available


  103. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
    PubMed     Text format     Abstract available


  104. LIU J, Yang Y, Wang H, Wang B, et al
    Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
    PubMed     Text format     Abstract available


  105. ELMI M, Sequeira S, Azin A, Elnahas A, et al
    Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
    PubMed     Text format     Abstract available


  106. LI D, McCall LM, Hahn OM, Hudis CA, et al
    Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Breast Cancer Res Treat. 2018 May 22. pii: 10.1007/s10549-018-4828.
    PubMed     Text format     Abstract available


  107. MASUMOTO N, Kadoya T, Sasada S, Emi A, et al
    Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Breast Cancer Res Treat. 2018 May 19. pii: 10.1007/s10549-018-4791.
    PubMed     Text format     Abstract available


  108. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    PubMed     Text format     Abstract available


  109. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    PubMed     Text format     Abstract available


  110. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    PubMed     Text format     Abstract available


  111. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    PubMed     Text format     Abstract available


  112. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    PubMed     Text format     Abstract available


  113. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    PubMed     Text format     Abstract available


  114. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    PubMed     Text format     Abstract available


  115. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    PubMed     Text format     Abstract available


  116. LOWRY KP, Braunstein LZ, Economopoulos KP, Salama L, et al
    Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4808.
    PubMed     Text format     Abstract available


  117. WANG S, Beeghly-Fadiel A, Cai Q, Cai H, et al
    Gene expression in triple-negative breast cancer in relation to survival.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4816.
    PubMed     Text format     Abstract available


  118. HUANG Z, Shi Y, Bao P, Cai H, et al
    Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4805.
    PubMed     Text format     Abstract available


  119. BARDIA A, Gucalp A, DaCosta N, Gabrail N, et al
    Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4813.
    PubMed     Text format     Abstract available


  120. CHOI JY, Cho EY, Choi YJ, Lee JH, et al
    Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4809.
    PubMed     Text format     Abstract available


  121. CUI P, Zhao Y, Chu X, He N, et al
    SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4814.
    PubMed     Text format     Abstract available


  122. DANIELS B, Kiely BE, Lord SJ, Houssami N, et al
    Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4804.
    PubMed     Text format     Abstract available


  123. TELLI ML, Stover DG, Loi S, Aparicio S, et al
    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4807.
    PubMed     Text format     Abstract available


  124. TSUNASHIMA R, Naoi Y, Shimazu K, Kagara N, et al
    Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4812.
    PubMed     Text format     Abstract available


  125. ABRAHAM J, Coleman R, Elias A, Holmes FA, et al
    Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4783.
    PubMed     Text format     Abstract available


  126. WUNDERLE M, Gass P, Haberle L, Flesch VM, et al
    BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Breast Cancer Res Treat. 2018 May 3. pii: 10.1007/s10549-018-4797.
    PubMed     Text format     Abstract available


  127. KOMMALAPATI A, Tella SH, Goyal G, Ganti AK, et al
    A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4802.
    PubMed     Text format     Abstract available


  128. ERIN N, Ogan N, Yerlikaya A
    Correction to: Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4781.
    PubMed     Text format     Abstract available


    April 2018
  129. KIM S, Ko Y, Lee HJ, Lim JE, et al
    Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
    Breast Cancer Res Treat. 2018 Apr 30. pii: 10.1007/s10549-018-4782.
    PubMed     Text format     Abstract available


  130. SHIMA H, Kida K, Adachi S, Yamada A, et al
    Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4793.
    PubMed     Text format     Abstract available


  131. VOCI A, Lee D, Ho E, Crane-Okada R, et al
    Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4790.
    PubMed     Text format     Abstract available


  132. BACHAND J, Soulos PR, Herrin J, Pollack CE, et al
    Physician peer group characteristics and timeliness of breast cancer surgery.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4789.
    PubMed     Text format     Abstract available


  133. HAQUE W, Verma V, Hatch S, Suzanne Klimberg V, et al
    Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4801.
    PubMed     Text format     Abstract available


  134. SOPIK V, Narod SA
    The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4796.
    PubMed     Text format     Abstract available


  135. HACKETT J, Thorneloe R, Side L, Wolf M, et al
    Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4775.
    PubMed     Text format     Abstract available


  136. O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
    PubMed     Text format     Abstract available


  137. KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
    PubMed     Text format     Abstract available


  138. SOARES FALCETTA F, de Araujo Vianna Trasel H, de Almeida FK, Rangel Ribeiro Falcetta M, et al
    Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4786.
    PubMed     Text format     Abstract available


  139. VERMA S, O'Shaughnessy J, Burris HA, Campone M, et al
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4769.
    PubMed     Text format     Abstract available


  140. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
    Breast Cancer Res Treat. 2018 Apr 12. pii: 10.1007/s10549-018-4784.
    PubMed     Text format     Abstract available


  141. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2018 Apr 11. pii: 10.1007/s10549-018-4780.
    PubMed     Text format     Abstract available


  142. LARSEN SB, Torstensson M, Kenborg L, Christensen J, et al
    Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 10. pii: 10.1007/s10549-018-4771.
    PubMed     Text format     Abstract available


  143. KUROZUMI S, Joseph C, Sonbul S, Gorringe KL, et al
    Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Breast Cancer Res Treat. 2018 Apr 9. pii: 10.1007/s10549-018-4777.
    PubMed     Text format     Abstract available


  144. PETROSSIAN K, Nguyen D, Lo C, Kanaya N, et al
    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4779.
    PubMed     Text format     Abstract available


  145. CHECK DK, Chawla N, Kwan ML, Pinheiro L, et al
    Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4776.
    PubMed     Text format     Abstract available


  146. RAU KM, Ou-Yang F, Chao TC, Kuo YL, et al
    Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4778.
    PubMed     Text format     Abstract available


  147. GHILLI M, Mariniello MD, Scatena C, Dosa L, et al
    Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.
    Breast Cancer Res Treat. 2018 Apr 3. pii: 10.1007/s10549-018-4772.
    PubMed     Text format     Abstract available


  148. SCHWARTZ MD, Peshkin BN, Isaacs C, Willey S, et al
    Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 2. pii: 10.1007/s10549-018-4773.
    PubMed     Text format     Abstract available


    March 2018
  149. MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
    Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
    PubMed     Text format     Abstract available


  150. CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
    Validation of a personalized risk prediction model for contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
    PubMed     Text format     Abstract available


  151. BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
    PubMed     Text format     Abstract available


  152. CAI H, Guo W, Zhang S, Li N, et al
    A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
    PubMed     Text format     Abstract available


  153. PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
    Prediction of breast cancer risk with volatile biomarkers in breath.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
    PubMed     Text format     Abstract available


  154. RISI E, Grilli A, Migliaccio I, Biagioni C, et al
    A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4766.
    PubMed     Text format     Abstract available


  155. AGERSBORG S, Mixon C, Nguyen T, Aithal S, et al
    Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4755.
    PubMed     Text format     Abstract available


  156. HILL DA, Friend S, Lomo L, Wiggins C, et al
    Breast cancer survival, survival disparities, and guideline-based treatment.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
    PubMed     Text format     Abstract available


  157. DUFFY MJ, Synnott NC, Crown J
    Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4753.
    PubMed     Text format     Abstract available


  158. CHATTERJEE S, Chaubal R, Maitra A, Gardi N, et al
    Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4749.
    PubMed     Text format     Abstract available


  159. BOYD J
    A parallel model for breast cancer metastasis.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4759.
    PubMed     Text format    


  160. SCHAYEK H, Korach H, Laitman Y, Bernstein-Molho R, et al
    Mutational analysis of candidate genes in Israeli male breast cancer cases.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4765.
    PubMed     Text format     Abstract available


  161. LI M, Zhou Y, Xia T, Zhou X, et al
    Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4757.
    PubMed     Text format     Abstract available


  162. ALTUNDAG K
    Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4762.
    PubMed     Text format    


  163. ERIN N, Ogan N, Yerlikaya A
    Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4752.
    PubMed     Text format     Abstract available


  164. THONE K, Rudolph A, Obi N, Chang-Claude J, et al
    Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
    Breast Cancer Res Treat. 2018 Mar 19. pii: 10.1007/s10549-018-4754.
    PubMed     Text format     Abstract available


  165. KYKER-SNOWMAN K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, et al
    A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4742.
    PubMed     Text format     Abstract available


  166. ANGARITA FA, Acuna SA, Cordeiro E, Elnahas A, et al
    Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4747.
    PubMed     Text format     Abstract available


  167. BOUYA S, Koochakzai M, Rafiemanesh H, Balouchi A, et al
    Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review.
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4750.
    PubMed     Text format     Abstract available


  168. NAROD SA
    Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4739.
    PubMed     Text format    


  169. WILSON LE, Pollack CE, Greiner MA, Dinan MA, et al
    Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Breast Cancer Res Treat. 2018 Mar 13. pii: 10.1007/s10549-018-4746.
    PubMed     Text format     Abstract available


  170. TURNER TH, Alzubi MA, Sohal SS, Olex AL, et al
    Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Mar 12. pii: 10.1007/s10549-018-4748.
    PubMed     Text format     Abstract available


  171. ROY P, Leizorovicz A, Villet R, Mercier C, et al
    Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
    Breast Cancer Res Treat. 2018 Mar 10. pii: 10.1007/s10549-018-4733.
    PubMed     Text format     Abstract available


  172. LI Y, Opyrchal M, Yao S, Peng X, et al
    The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Breast Cancer Res Treat. 2018 Mar 9. pii: 10.1007/s10549-018-4745.
    PubMed     Text format     Abstract available


  173. BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
    Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
    PubMed     Text format     Abstract available


  174. BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
    Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
    PubMed     Text format     Abstract available


  175. PARK SJ, Lee MH, Kong SY, Song MK, et al
    Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
    PubMed     Text format     Abstract available


  176. VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
    Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
    PubMed     Text format     Abstract available


  177. ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
    Preoperative breast MRI and mortality in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
    PubMed     Text format     Abstract available


  178. ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
    Exercise and weight loss interventions and miRNA expression in women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
    PubMed     Text format     Abstract available


  179. CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
    Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
    PubMed     Text format     Abstract available


  180. RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
    Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
    PubMed     Text format     Abstract available


    February 2018
  181. GERNAAT SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, et al
    The risk of cardiovascular disease following breast cancer by Framingham risk score.
    Breast Cancer Res Treat. 2018 Feb 28. pii: 10.1007/s10549-018-4723.
    PubMed     Text format     Abstract available


  182. KUSHNER CJ, Hwang WT, Wang S, Solin LJ, et al
    Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer.
    Breast Cancer Res Treat. 2018 Feb 27. pii: 10.1007/s10549-018-4729.
    PubMed     Text format     Abstract available


  183. CHEN R, Ye Y, Yang C, Peng Y, et al
    Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4730.
    PubMed     Text format     Abstract available


  184. BRONTE G, Ravaioli S, Bravaccini S
    What to look for in cell-free DNA from breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4728.
    PubMed     Text format    


  185. CHENG J, Burwinkel B
    Cell-free DNA in breast cancer: a long way to go.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4731.
    PubMed     Text format    


  186. EBER-SCHULZ P, Tariku W, Reibold C, Addissie A, et al
    Survival of breast cancer patients in rural Ethiopia.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4724.
    PubMed     Text format     Abstract available


  187. DE VRIES YC, Boesveldt S, Kelfkens CS, Posthuma EE, et al
    Taste and smell perception and quality of life during and after systemic therapy for breast cancer.
    Breast Cancer Res Treat. 2018 Feb 23. pii: 10.1007/s10549-018-4720.
    PubMed     Text format     Abstract available


  188. CLIFTON K, Gutierrez-Barrera A, Ma J, Bassett R Jr., et al
    Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4727.
    PubMed     Text format     Abstract available


  189. BAUMANN FT, Reike A, Reimer V, Schumann M, et al
    Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4725.
    PubMed     Text format     Abstract available


  190. CHA YJ, Kim ES, Koo JS
    Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4722.
    PubMed     Text format     Abstract available


  191. JOHNSON J, Bessette DC, Saunus JM, Smart CE, et al
    Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4719.
    PubMed     Text format     Abstract available


  192. RUIZ A, Sebagh M, Wicherts DA, Castro-Benitez C, et al
    Long-term survival and cure model following liver resection for breast cancer metastases.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4714.
    PubMed     Text format     Abstract available


  193. RUDOLPH M, Sizemore ST, Lu Y, Teng KY, et al
    A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4718.
    PubMed     Text format     Abstract available


  194. WEISS A, Menen RS, Lin HY, Shen Y, et al
    Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4715.
    PubMed     Text format     Abstract available


  195. TOT T
    Metastasis of breast cancer prior to invasion.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4721.
    PubMed     Text format    


  196. JACOBS DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, et al
    Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4712.
    PubMed     Text format     Abstract available


  197. TOLKACH Y, Gevensleben H, Bundschuh R, Koyun A, et al
    Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4717.
    PubMed     Text format     Abstract available


  198. WAGNER LI, Zhao F, Goss PE, Chapman JW, et al
    Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4713.
    PubMed     Text format     Abstract available


  199. SCHAIRER C, Freedman DM, Gadalla SM, Pfeiffer RM, et al
    Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.
    Breast Cancer Res Treat. 2018 Feb 15. pii: 10.1007/s10549-018-4680.
    PubMed     Text format     Abstract available


  200. SHOEMAKER ML, White MC, Wu M, Weir HK, et al
    Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4699.
    PubMed     Text format     Abstract available


  201. GIANNAKEAS V, Sopik V, Narod SA
    A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4716.
    PubMed     Text format     Abstract available


  202. DEHDASHTI F, Wu N, Bose R, Naughton MJ, et al
    Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4696.
    PubMed     Text format     Abstract available


  203. COLLARINO A, Valdes Olmos RA, van Berkel LGAJ, Neijenhuis PA, et al
    The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4706.
    PubMed     Text format     Abstract available


  204. CHANG JH, Shin KH, Ahn SD, Park HJ, et al
    Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4707.
    PubMed     Text format     Abstract available


  205. HOLLINGSWORTH AB
    Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4702.
    PubMed     Text format    


  206. XIE B, Yuan Z, Yang Y, Sun Z, et al
    MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4708.
    PubMed     Text format     Abstract available


  207. SKAANE P, Sebuodegard S, Bandos AI, Gur D, et al
    Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4705.
    PubMed     Text format     Abstract available


  208. DE MULDER H, Laenen A, Wildiers H, Punie K, et al
    Breast cancer subtype and survival by parity and time since last birth.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4701.
    PubMed     Text format     Abstract available


  209. MIYAKE KK, Nakamoto Y, Saji S, Sugie T, et al
    Impact of physiological hormonal fluctuations on (18)F-fluorodeoxyglucose uptake in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4711.
    PubMed     Text format     Abstract available


  210. GOLDVASER H, Majeed H, Ribnikar D, Seruga B, et al
    Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4710.
    PubMed     Text format     Abstract available


  211. COSTA RLB, Han HS, Gradishar WJ
    Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Breast Cancer Res Treat. 2018 Feb 7. pii: 10.1007/s10549-018-4697.
    PubMed     Text format     Abstract available


  212. ZAREI N, Fazeli M, Mohammadi M, Nejatollahi F, et al
    Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
    Breast Cancer Res Treat. 2018 Feb 6. pii: 10.1007/s10549-017-4641.
    PubMed     Text format     Abstract available


  213. LAMMERT J, Lubinski J, Gronwald J, Huzarski T, et al
    Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-018-4694.
    PubMed     Text format     Abstract available


  214. JANNI W, Alba E, Bachelot T, Diab S, et al
    First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-017-4658.
    PubMed     Text format     Abstract available


  215. VALDORA F, Houssami N, Rossi F, Calabrese M, et al
    Rapid review: radiomics and breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-018-4675.
    PubMed     Text format     Abstract available


  216. FOLDI J, Mougalian S, Silber A, Lannin D, et al
    Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-017-4653.
    PubMed     Text format     Abstract available


  217. ZHOU S, Wang L, Yang Q, Liu H, et al
    Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4678.
    PubMed     Text format     Abstract available


  218. MATOSSIAN MD, Burks HE, Bowles AC, Elliott S, et al
    A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4685.
    PubMed     Text format     Abstract available


    January 2018
  219. LEE SB, Sohn G, Kim J, Chung IY, et al
    A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Breast Cancer Res Treat. 2018 Jan 31. pii: 10.1007/s10549-018-4682.
    PubMed     Text format     Abstract available


  220. HWANG KT, Kim EK, Jung SH, Lee ES, et al
    Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Breast Cancer Res Treat. 2018 Jan 30. pii: 10.1007/s10549-018-4681.
    PubMed     Text format     Abstract available


  221. JANSSON S, Aaltonen K, Bendahl PO, Falck AK, et al
    The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Breast Cancer Res Treat. 2018 Jan 29. pii: 10.1007/s10549-018-4664.
    PubMed     Text format     Abstract available


  222. FAIRWEATHER M, Jiang W, Keating NL, Freedman RA, et al
    Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry.
    Breast Cancer Res Treat. 2018 Jan 27. pii: 10.1007/s10549-018-4689.
    PubMed     Text format     Abstract available


  223. ZHANG L, Yu Q, Wu XC, Hsieh MC, et al
    Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-017-4646.
    PubMed     Text format     Abstract available


  224. GOYAL NG, Levine BJ, Van Zee KJ, Naftalis E, et al
    Trajectories of quality of life following breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-018-4677.
    PubMed     Text format     Abstract available


  225. POURCELOT C, Orillard E, Nallet G, Dirand C, et al
    Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
    Breast Cancer Res Treat. 2018 Jan 23. pii: 10.1007/s10549-018-4676.
    PubMed     Text format     Abstract available


  226. FAN Z, Ouyang T, Li J, Wang T, et al
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Jan 22. pii: 10.1007/s10549-018-4673.
    PubMed     Text format     Abstract available


  227. JONES T, Duquette D, Underhill M, Ming C, et al
    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-018-4674.
    PubMed     Text format     Abstract available


  228. NAROD SA, Sopik V
    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-017-4644.
    PubMed     Text format     Abstract available


  229. BAO T, Seidman A, Li Q, Seluzicki C, et al
    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4670.
    PubMed     Text format     Abstract available


  230. ABRAHAM J, Caldera H, Coleman R, Elias A, et al
    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4662.
    PubMed     Text format     Abstract available


  231. MIJWEL S, Backman M, Bolam KA, Olofsson E, et al
    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4663.
    PubMed     Text format     Abstract available


  232. PEDERSON HJ, Hussain N, Noss R, Yanda C, et al
    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-017-4643.
    PubMed     Text format     Abstract available


  233. KOOPMAN T, Buikema HJ, Hollema H, de Bock GH, et al
    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4669.
    PubMed     Text format     Abstract available


  234. BREYER JZ, Wendland EM, Kops NL, Caleffi M, et al
    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat. 2018 Jan 17. pii: 10.1007/s10549-017-4655.
    PubMed     Text format     Abstract available


  235. GARCIA GARRE E, Luengo Gil G, Montoro Garcia S, Gonzalez Billalabeitia E, et al
    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4656.
    PubMed     Text format     Abstract available


  236. CHENG J, Holland-Letz T, Wallwiener M, Surowy H, et al
    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-018-4666.
    PubMed     Text format     Abstract available


  237. NI YB, Tsang JYS, Shao MM, Chan SK, et al
    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4645.
    PubMed     Text format     Abstract available


  238. FOSTIRA F, Saloustros E, Apostolou P, Vagena A, et al
    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-018-4661.
    PubMed     Text format     Abstract available


  239. JAKIMOVSKA M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, et al
    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4642.
    PubMed     Text format     Abstract available


  240. LAMBERTINI M, Fontanella C
    How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4654.
    PubMed     Text format    


  241. POORVU PD, Vaz-Luis I, Freedman RA, Lin NU, et al
    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4659.
    PubMed     Text format     Abstract available


  242. ZHANG Y, Ji Y, Li J, Lei L, et al
    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4660.
    PubMed     Text format     Abstract available


  243. PAN K, Hurria A, Chlebowski RT
    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-017-4650.
    PubMed     Text format     Abstract available


  244. PAN Y, Heisig SR, von Blanckenburg P, Albert US, et al
    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4637.
    PubMed     Text format     Abstract available


  245. NUNCIA-CANTARERO M, Martinez-Canales S, Andres-Pretel F, Santpere G, et al
    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4652.
    PubMed     Text format     Abstract available


  246. TAN Q, Wei C
    Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4648.
    PubMed     Text format    


  247. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 11. pii: 10.1007/s10549-017-4634.
    PubMed     Text format     Abstract available



  248. 1st UK Interdisciplinary Breast Cancer Symposium-15th-16th January 2018.
    Breast Cancer Res Treat. 2018 Jan 10. pii: 10.1007/s10549-017-4585.
    PubMed     Text format    


  249. LILJEGREN A, von Wachenfeldt A, Azavedo E, Eloranta S, et al
    Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Breast Cancer Res Treat. 2018 Jan 9. pii: 10.1007/s10549-017-4639.
    PubMed     Text format     Abstract available


  250. CHAE JW, Chua PS, Ng T, Yeo AHL, et al
    Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Breast Cancer Res Treat. 2018 Jan 8. pii: 10.1007/s10549-017-4640.
    PubMed     Text format     Abstract available


  251. BRAVACCINI S, Rocca A, Bronte G
    Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 6. pii: 10.1007/s10549-017-4630.
    PubMed     Text format    


  252. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 5. pii: 10.1007/s10549-017-4633.
    PubMed     Text format     Abstract available


  253. WANG S, Qian F, Zheng Y, Ogundiran T, et al
    Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    Breast Cancer Res Treat. 2018 Jan 4. pii: 10.1007/s10549-017-4638.
    PubMed     Text format     Abstract available


  254. KOSTEV K, Kalder M
    20-year risk of breast cancer recurrence.
    Breast Cancer Res Treat. 2018 Jan 3. pii: 10.1007/s10549-017-4636.
    PubMed     Text format    


    December 2017
  255. HADDAD TC, D'Assoro A, Suman V, Opyrchal M, et al
    Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 30. pii: 10.1007/s10549-017-4616.
    PubMed     Text format     Abstract available


  256. PONDE N, Bradbury I, Lambertini M, Ewer M, et al
    Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Breast Cancer Res Treat. 2017 Dec 27. pii: 10.1007/s10549-017-4628.
    PubMed     Text format     Abstract available


  257. KOSTEV K, Kalder M
    Long-term use of basal insulin and the risk of breast cancer.
    Breast Cancer Res Treat. 2017 Dec 26. pii: 10.1007/s10549-017-4631.
    PubMed     Text format    


  258. TELLI ML, Hellyer J, Audeh W, Jensen KC, et al
    Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Breast Cancer Res Treat. 2017 Dec 23. pii: 10.1007/s10549-017-4624.
    PubMed     Text format     Abstract available


  259. FAZZINO TL, Klemp J, Befort C
    Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.
    Breast Cancer Res Treat. 2017 Dec 22. pii: 10.1007/s10549-017-4603.
    PubMed     Text format     Abstract available


  260. PICHILINGUE-FEBRES AF, Arias-Linares MA, Araujo-Castillo RV
    Comments on "Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors" by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat. 2017 Dec 21. pii: 10.1007/s10549-017-4620.
    PubMed     Text format     Abstract available


  261. UNDERWOOD EA, Rochon PA, Moineddin R, Lee PE, et al
    Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2017 Dec 20. pii: 10.1007/s10549-017-4627.
    PubMed     Text format     Abstract available


  262. DUGGAN C, Baumgartner RN, Baumgartner KB, Bernstein L, et al
    Genetic variation in TNFalpha, PPARgamma, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4621.
    PubMed     Text format     Abstract available


  263. VAN SEIJEN M, Mooyaart AL, Mulder L, Hoogstraat M, et al
    Enrichment of high-grade tumors in breast cancer gene expression studies.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4622.
    PubMed     Text format     Abstract available


  264. KWAN ML, Yao S, Laurent CA, Roh JM, et al
    Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2017 Dec 16. pii: 10.1007/s10549-017-4626.
    PubMed     Text format     Abstract available


  265. DU RUSQUEC P, Palpacuer C, Campion L, Patsouris A, et al
    Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4623.
    PubMed     Text format     Abstract available


  266. NAROD SA, Huzarski T, Gronwald J, Byrski T, et al
    Predictors of survival for breast cancer patients with a BRCA1 mutation.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4605.
    PubMed     Text format     Abstract available


  267. ZIMMER AS, Zhu K, Steeg PS, Wu A, et al
    Analysis of breast cancer in young women in the Department of Defense (DOD) database.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4615.
    PubMed     Text format     Abstract available


  268. FALANDRY C, Krakowski I, Cure H, Carola E, et al
    Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.
    Breast Cancer Res Treat. 2017 Dec 14. pii: 10.1007/s10549-017-4607.
    PubMed     Text format     Abstract available


  269. FANG H, Huang D, Yang F, Guan X, et al
    Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Dec 13. pii: 10.1007/s10549-017-4612.
    PubMed     Text format     Abstract available


  270. HAN SN, Amant F, Cardonick EH, Loibl S, et al
    Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4611.
    PubMed     Text format     Abstract available


  271. BENS A, Papadopoulos FC, Pukkala E, Ekbom A, et al
    Worse survival after breast cancer in women with anorexia nervosa.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4618.
    PubMed     Text format     Abstract available


  272. VAN VULPEN JK, Schmidt ME, Velthuis MJ, Wiskemann J, et al
    Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4608.
    PubMed     Text format     Abstract available


  273. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4601.
    PubMed     Text format     Abstract available


  274. SPEIGL L, Burow H, Bailur JK, Janssen N, et al
    CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4594.
    PubMed     Text format     Abstract available


  275. XIE J, Cao J, Wang JF, Zhang BH, et al
    Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4609.
    PubMed     Text format     Abstract available


  276. SINGH K, He X, Kalife ET, Ehdaivand S, et al
    Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4619.
    PubMed     Text format     Abstract available


  277. LI W, Kwok CC, Chan DC, Wang F, et al
    Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4614.
    PubMed     Text format     Abstract available


  278. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4578.
    PubMed     Text format     Abstract available


  279. IBRAHIM MFK, Hilton J, Mazzarello S, Fergusson D, et al
    A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4604.
    PubMed     Text format     Abstract available


  280. WANG J, Fan T, He Y, Chen X, et al
    (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4591.
    PubMed     Text format     Abstract available


  281. PISTILLI B, Pluard T, Urruticoechea A, Farci D, et al
    Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Breast Cancer Res Treat. 2017 Dec 2. pii: 10.1007/s10549-017-4596.
    PubMed     Text format     Abstract available


    November 2017
  282. REINERT T, Debiasi M, Bines J, Barrios CH, et al
    Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4593.
    PubMed     Text format     Abstract available


  283. XIA Z, Baumgartner KB, Baumgartner RN, Boone SD, et al
    Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4600.
    PubMed     Text format     Abstract available


  284. MATIKAS A, Margolin S, Hellstrom M, Johansson H, et al
    Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4599.
    PubMed     Text format     Abstract available


  285. YU YF, Wang Y, Fu TP, Chen K, et al
    Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 29. pii: 10.1007/s10549-017-4592.
    PubMed     Text format     Abstract available


  286. WANG Z, Kong J, Wu Y, Zhang J, et al
    PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4597.
    PubMed     Text format     Abstract available


  287. TRENTHAM-DIETZ A, Ergun MA, Alagoz O, Stout NK, et al
    Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4582.
    PubMed     Text format     Abstract available


  288. LOHRISCH C, Francl M, Sun S, Villa D, et al
    Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
    Breast Cancer Res Treat. 2017 Nov 27. pii: 10.1007/s10549-017-4586.
    PubMed     Text format     Abstract available


  289. VILLEGAS SL, Darb-Esfahani S, von Minckwitz G, Huober J, et al
    Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2017 Nov 25. pii: 10.1007/s10549-017-4581.
    PubMed     Text format     Abstract available


  290. LIU YL, Connolly EP, Kalinsky K
    Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4590.
    PubMed     Text format    


  291. PEZO RC, Chen TW, Berman HK, Mulligan AM, et al
    Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4580.
    PubMed     Text format     Abstract available


  292. ALTUNDAG K
    Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4589.
    PubMed     Text format    


  293. COLOMER R, Hall P, Szkultecka-Debek M, Bondi RC, et al
    Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Breast Cancer Res Treat. 2017 Nov 23. pii: 10.1007/s10549-017-4567.
    PubMed     Text format     Abstract available


  294. LECLERC M, Neuhausen SL, Schayek H, Laitman Y, et al
    Are VNTRs co-localizing with breast cancer-associated SNPs?
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4588.
    PubMed     Text format     Abstract available


  295. DIELI-CONWRIGHT CM, Parmentier JH, Sami N, Lee K, et al
    Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention.
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4576.
    PubMed     Text format     Abstract available


  296. O'SHAUGHNESSY J, Petrakova K, Sonke GS, Conte P, et al
    Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4518.
    PubMed     Text format     Abstract available


  297. NILSSON MP, Torngren T, Henriksson K, Kristoffersson U, et al
    BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4584.
    PubMed     Text format     Abstract available


  298. ASLEH K, Won JR, Gao D, Voduc KD, et al
    Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4583.
    PubMed     Text format     Abstract available


  299. BROUCKAERT O, Van Asten K, Laenen A, Soubry A, et al
    Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4579.
    PubMed     Text format     Abstract available


  300. RIER HN, Jager A, Sleijfer S, van Rosmalen J, et al
    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574.
    PubMed     Text format     Abstract available


  301. ABDEL-RAHMAN O
    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat. 2017 Nov 15. doi: 10.1007/s10549-017-4577.
    PubMed     Text format     Abstract available


  302. MIJWEL S, Backman M, Bolam KA, Jervaeus A, et al
    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4571.
    PubMed     Text format     Abstract available


  303. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4568.
    PubMed     Text format     Abstract available


  304. MENESES K, Benz R, Bail JR, Vo JB, et al
    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4564.
    PubMed     Text format     Abstract available


  305. DODSON A, Okonji D, Assersohn L, Rigg A, et al
    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514.
    PubMed     Text format     Abstract available


  306. BOSTNER J, Alayev A, Berman AY, Fornander T, et al
    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4508.
    PubMed     Text format     Abstract available


  307. GILLMAN AS, Gardiner CK, Koljack CE, Bryan AD, et al
    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4573.
    PubMed     Text format     Abstract available


  308. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4569.
    PubMed     Text format     Abstract available


  309. KWA M, Li X, Novik Y, Oratz R, et al
    Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570.
    PubMed     Text format     Abstract available


  310. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4565.
    PubMed     Text format     Abstract available


  311. LYNCE F, Blackburn MJ, Cai L, Wang H, et al
    Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4563.
    PubMed     Text format     Abstract available


  312. SOPIK V, Sun P, Narod SA
    Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4572.
    PubMed     Text format     Abstract available


  313. BRIANESE RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, et al
    BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4552.
    PubMed     Text format     Abstract available


  314. EVANS DG, Harkness EF, Howel S, Woodward ER, et al
    Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4557.
    PubMed     Text format     Abstract available


  315. GOING CC, Alexandrova L, Lau K, Yeh CY, et al
    Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4562.
    PubMed     Text format     Abstract available


  316. MURPHY BL, Zalewski NL, Degnim AC, McKeon A, et al
    Breast cancer-related paraneoplastic neurologic disease.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4566.
    PubMed     Text format     Abstract available


  317. RIMAWI MF, De Angelis C, Contreras A, Pareja F, et al
    Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4533.
    PubMed     Text format     Abstract available


  318. LAMBERT LK, Balneaves LG, Howard AF, Gotay CC, et al
    Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4561.
    PubMed     Text format     Abstract available


  319. KIRKHAM AA, Eves ND, Shave RE, Bland KA, et al
    The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4554.
    PubMed     Text format     Abstract available


  320. FREEDMAN RA, Tolaney SM
    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast Cancer Res Treat. 2017 Nov 4. doi: 10.1007/s10549-017-4560.
    PubMed     Text format     Abstract available


  321. RODRIGUEZ-WALLBERG KA, Eloranta S, Krawiec K, Lissmats A, et al
    Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Breast Cancer Res Treat. 2017 Nov 2. doi: 10.1007/s10549-017-4555.
    PubMed     Text format     Abstract available


    October 2017
  322. NGUYEN F, Pena L, Ibisch C, Loussouarn D, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4548.
    PubMed     Text format     Abstract available


  323. RABOW M, Small R, Jow A, Majure M, et al
    The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4556.
    PubMed     Text format     Abstract available


  324. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Oct 25. doi: 10.1007/s10549-017-4539.
    PubMed     Text format     Abstract available


  325. BOCK CH, Jay AM, Dyson G, Beebe-Dimmer JL, et al
    The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.
    Breast Cancer Res Treat. 2017 Oct 24. doi: 10.1007/s10549-017-4521.
    PubMed     Text format     Abstract available


  326. DIRIX LY, Takacs I, Jerusalem G, Nikolinakos P, et al
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4537.
    PubMed     Text format     Abstract available


  327. ABADIE J, Nguyen F, Loussouarn D, Pena L, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4542.
    PubMed     Text format     Abstract available


  328. ALTUNDAG K
    Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4544.
    PubMed     Text format    


  329. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4541.
    PubMed     Text format     Abstract available


  330. SONKE GS, Hart LL, Campone M, Erdkamp F, et al
    Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Oct 22. doi: 10.1007/s10549-017-4523.
    PubMed     Text format     Abstract available


  331. TAN Q, Qin Q
    Does the elevation of CAMLs predict metastatic breast cancer patients' survival?
    Breast Cancer Res Treat. 2017 Oct 20. doi: 10.1007/s10549-017-4546.
    PubMed     Text format    


  332. MORDANG JJ, Gubern-Merida A, Bria A, Tortorella F, et al
    The importance of early detection of calcifications associated with breast cancer in screening.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4527.
    PubMed     Text format     Abstract available


  333. LUBINSKI J, Marciniak W, Muszynska M, Huzarski T, et al
    Serum selenium levels predict survival after breast cancer.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4525.
    PubMed     Text format     Abstract available


  334. MALMGREN JA, Mayer M, Atwood MK, Kaplan HG, et al
    Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4529.
    PubMed     Text format     Abstract available


  335. SCHON K, Tischkowitz M
    Clinical implications of germline mutations in breast cancer: TP53.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4531.
    PubMed     Text format     Abstract available


  336. FIETZ T, Zahn MO, Kohler A, Engel E, et al
    Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4534.
    PubMed     Text format     Abstract available


  337. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4530.
    PubMed     Text format     Abstract available


  338. BERNSTEIN V, Ellard SL, Dent SF, Tu D, et al
    A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4538.
    PubMed     Text format     Abstract available


  339. ADACHI Y, Yoshimura M, Nishida K, Usuki H, et al
    Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
    Breast Cancer Res Treat. 2017 Oct 12. doi: 10.1007/s10549-017-4532.
    PubMed     Text format     Abstract available


  340. ALTUNDAG K
    Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
    Breast Cancer Res Treat. 2017 Oct 11. doi: 10.1007/s10549-017-4536.
    PubMed     Text format    


  341. DOMINICI LS, Sineshaw HM, Jemal A, Lin CC, et al
    Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Breast Cancer Res Treat. 2017 Oct 9. doi: 10.1007/s10549-017-4528.
    PubMed     Text format     Abstract available


  342. PAGE DB, Wen H, Brogi E, Dure D, et al
    Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Breast Cancer Res Treat. 2017 Oct 6. doi: 10.1007/s10549-017-4520.
    PubMed     Text format     Abstract available


  343. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Text format     Abstract available


    September 2017
  344. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Text format     Abstract available


  345. GALLARDO A, Lerma E
    Response letter to: Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4524.
    PubMed     Text format    


  346. ALTUNDAG K
    Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4515.
    PubMed     Text format    


  347. LUU T, Kim KP, Blanchard S, Anyang B, et al
    Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516.
    PubMed     Text format     Abstract available


  348. TSOUTSOU PG, Durham AD, Vozenin MC
    A need for biology-driven personalized radiotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4522.
    PubMed     Text format    


  349. SAYED S, Moloo Z, Wasike R, Bird P, et al
    Ethnicity and breast cancer characteristics in Kenya.
    Breast Cancer Res Treat. 2017 Sep 26. doi: 10.1007/s10549-017-4511.
    PubMed     Text format     Abstract available


  350. LIU YL, Saraf A, Catanese B, Lee SM, et al
    Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4507.
    PubMed     Text format     Abstract available


  351. CRONIN-FENTON D, Kjaersgaard A, Norgaard M, Amelio J, et al
    Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4510.
    PubMed     Text format     Abstract available


  352. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Erratum to: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Sep 20. doi: 10.1007/s10549-017-4505.
    PubMed     Text format     Abstract available


  353. RICE BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, et al
    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat. 2017 Sep 18. doi: 10.1007/s10549-017-4506.
    PubMed     Text format     Abstract available


  354. JEONG IJ, Lee SG, Kim YH, Ko BS, et al
    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4504.
    PubMed     Text format     Abstract available


  355. GIANNAKEAS V, Narod SA
    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4476.
    PubMed     Text format     Abstract available


  356. LEON-FERRE RA, Polley MY, Liu H, Gilbert JA, et al
    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499.
    PubMed     Text format     Abstract available


  357. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4501.
    PubMed     Text format     Abstract available


  358. SIEGELMANN-DANIELI N, Katzir I, Landes JV, Segal Y, et al
    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491.
    PubMed     Text format     Abstract available


  359. KOCHI M, Iwamoto T, Niikura N, Bianchini G, et al
    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4502.
    PubMed     Text format     Abstract available


  360. MASUNAGA N, Kagara N, Motooka D, Nakamura S, et al
    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4487.
    PubMed     Text format     Abstract available


  361. ROCQUE GB, Williams CP, Jones MI, Kenzik KM, et al
    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat. 2017 Sep 12. doi: 10.1007/s10549-017-4498.
    PubMed     Text format     Abstract available


  362. NIIKURA N, Shimomura A, Fukatsu Y, Sawaki M, et al
    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4489.
    PubMed     Text format     Abstract available


  363. GREGOROWITSCH ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, et al
    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495.
    PubMed     Text format     Abstract available


  364. SAUNUS JM, Smart CE, Kutasovic JR, Johnston RL, et al
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat. 2017 Sep 9. doi: 10.1007/s10549-017-4496.
    PubMed     Text format     Abstract available


    August 2017
  365. WEBER WP, Soysal SD, El-Tamer M, Sacchini V, et al
    First international consensus conference on standardization of oncoplastic breast conserving surgery.
    Breast Cancer Res Treat. 2017;165:139-149.
    PubMed     Text format     Abstract available


  366. CONT NT, Maggiorotto F, Martincich L, Rivolin A, et al
    Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.
    Breast Cancer Res Treat. 2017;165:85-95.
    PubMed     Text format     Abstract available


    June 2017
  367. SANTEN RJ, Radisky DC, Degnim A, Frost MH, et al
    Aromatase expression in atypical ductal hyperplasia in women.
    Breast Cancer Res Treat. 2017;163:623-629.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: